Inovio Pharmaceuticals, Inc. has announced the peer-reviewed publication of results from two phase I trials of its PENNVAX-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio's proprietary CELLECTRA electroporation delivery device.
http://www.medicalnewstoday.com/releases/263172.php
http://www.medicalnewstoday.com/releases/263172.php
No comments:
Post a Comment